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In countries such as the UK and the USA that are privileged 
to have adequate supplies of COVID-19 vaccines but 
are also plagued by histories of deep inequities and 
white supremacy, it was predictable that the benefits of 
COVID-19 vaccines would not be equally shared across all 
sectors of society. The challenge of low vaccine access and 
uptake by some groups is multidimensional. Although 
vaccine hesitancy is often implicated, this framing 
mistakenly places the responsibility on minoritised groups 
to become less hesitant, rather than on public health 
systems to become more trustworthy and accessible. This 
framing also inadvertently under emphasises barriers to 
vaccine access that have been incompletely addressed for 
these populations.
In a nationally representative UK survey of 12 035 people 
conducted during November and December, 2020, 
71·8% of Black and 42·3% of Pakistani and Bangladeshi 
respondents were “unlikely or very unlikely” to take the 
COVID-19 vaccine.1 Available data from 43 US states up 
to April, 2021, show that COVID-19 vaccination rates 
in White people were almost twice as high as rates in 
Hispanic and Black people,2 despite a higher proportion 
of White Republicans being unsure or unwilling when 
asked about taking a COVID-19 vaccine.3 Vaccine uptake 
disparities are not, therefore, fully explained by so-called 
vaccine hesitancy. There is an urgent need for government 
agencies to collect representative data to inform 
strategies to address disparities in vaccine uptake, such 
as data on vaccination rates disaggregated by ethnicity 
or race, on vaccine availability by location, and on more 
complex reasons for vaccine refusals, including previous 
negative experiences of interacting with government 
services and locations or timings of vaccination centres 
being inconvenient.2,4
Insights from quantitative and qualitative data need 
to inform strategies to increase vaccination rates among 
groups with low uptake. Misattribution of the drivers of 
vaccine inequities can lead to inappropriately tailored 
solutions. The term vaccine hesitancy typically implies 
that individuals or communities are choosing not to take 
the vaccine on the grounds of low confidence or incorrect 
beliefs.5 However, a UK study that included data from a 
2600-people survey and qualitative interviews showed 
that twice as many Asian and Black respondents have 
faced discrimination when accessing local services, such 
as the police, than the White population.6 The study also 
indicated that past experiences of such discrimination—
eg, respondents stating that services “actively make my 
life more difficult”—are associated with lower vaccine 
uptake.6 Failures to acknowledge institutional racism, as 
exemplified by the March, 2021, UK Commission on Race 
and Ethnic Disparities report,7 prevent concerted efforts 
to tackle structural barriers and their practical impacts. In 
addition to previous discrimination when accessing local 
public health, justice, or social services, other barriers 
include no or inadequate health insurance, insufficient 
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access to information to address patients’ justified 
questions about possible adverse events, and concerns 
related to historical practices of minoritised groups being 
unethically exploited in medical experiments.8,9 With 
respect to the latter, Black Britons or Americans might 
question whether pharmaceutical companies and public 
health services are fully informing and protecting them, 
knowing that this was not the case in past programmes 
such as the US Tuskegee syphilis study or when 
experimental drugs were used on Nigerian children and 
there were concerns about whether appropriate informed 
consent was obtained from parents.9,10 Fears that certain 
populations might be misled about vaccines11 and have 
no recourse against powerful pharmaceutical companies 
if they are harmed, alongside other structural barriers, 
will not be addressed by translating information about 
vaccine into different languages, or leveraging so-called 
vaccine hesitancy to shift responsibility on to minoritised 
groups. Ultimately, investments in health information 
will be most effective when the groups that information 
is tailored for trust health services more than they trust 
other non-medical sources of advice.11
Learning from countries that have responded to vaccine 
uptake challenges, such as Pakistan, can be instructive. 
Experience from Pakistan suggests that although it is 
crucial to offer free vaccines at the point of care and 
without any legal residency checks, this is not sufficient 
to ensure high vaccine uptake in groups in which the 
state has been previously coercive or absent in providing 
health-care or other public services.12 A parallel could be 
drawn with both immigrant and minority populations 
in the UK and USA, whose past or current experiences 
of discrimination with government services, including 
health care, such as being treated differently when 
seeking help or spoken to rudely, might act as a barrier 
to vaccine uptake.9 Misinformation and disinformation 
spread through social media and poorly informed 
commentators on mass media platforms are unresolved 
challenges in Pakistan and other countries,11 and there 
are no quick fixes for strengthening the credible sources 
of health information, health journalism, and media 
regulation.13 As WHO emphasises, COVID-19 has only 
exacerbated the infodemic challenge; the rapid increase 
in volume of health-related information, both accurate 
and inaccurate, makes monitoring and management 
resource intensive.14. Part of the solution lies in sufficiently 
resourcing trusted, local health-care providers to take 
the time needed to listen to local community concerns, 
address specific fears, counter misinformation, build 
trust with local communities, and convince people of the 
benefits of taking the vaccine. Evidence from Pakistan 
indicates that a vicious cycle can occur when health-care 
providers do not have the tools or counter-narrative 
to address disinformation during vaccine encounters, 
and therefore hurry interactions with patients that may 
benefit from lengthy discussions.15 Thus, if the push to 
roll out COVID-19 vaccinations rapidly results in health-
care providers being insufficiently supported to address 
any concerns they encounter, this can result in health 
professionals appearing dismissive, thereby exacerbating 
low trust.12,15 Not prioritising community-centred 
engagement can also falsely implicate patients as being 
poor at understanding or being untrusting. A key lesson 
that Pakistan offers is the importance of acknowledging 
that there will be different types of rational concerns or 
information gaps among different communities and one-
size-fits-all reassurances are unlikely to work.12
An evidence-based understanding of, and response 
to, the unique needs of communities with low vaccine 
uptake will allow policy makers to move beyond focusing 
on individual choices and help address the underlying 
causes of low vaccine uptake, including lack of confidence 
in vaccines and health-care services and governments 
services more broadly, as well as issues related to 
convenience of access. Supporting vaccine uptake in 
communities that have already been disproportionately 
affected by COVID-19 is an equity issue and will also 
help achieve broader population immunity. Since there 
have been delays in collecting complete, localised data 
on vaccination rates disaggregated by ethnicity or race 
and reasons for vaccination acceptance or refusal in 
the UK and USA, learning lessons from other countries 
is important.2,4 Indeed, it is not too late for the UK and 
USA to improve their track records of learning from other 
contexts and prioritising the needs of disadvantaged 
groups during this pandemic.
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Prostate cancer is the second most frequent cancer in 
men, and there were about 1·4 million new cases around 
the world in 2020.1,2 Prostate cancer accounts for an 
estimated 15% of all cancer cases in men worldwide 
and is the most common form of cancer in men in in 
112 countries (figure). Globally, there are many hundreds 
of thousands of premature deaths from prostate cancer 
annually,3 and a huge toll in morbidity, particularly bone 
metastases leading to pain, fracture, and disability.4 
Curative treatment itself can also cause adverse effects on 
urinary and sexual function.5 There is a growing tension 
between the need to diagnose advanced disease early 
while not overdiagnosing lower risk disease that probably 
does not need treatment.
Health systems and providers in low-income and middle-
income countries (LMICs) are confronted with the chal-
lenges of disease burden, late diagnosis, and reduced 
access to specialist services and treatment. In high-income 
countries, only 5–15% of men present with metastatic 
disease, for which curative treatment is no longer possible,6 
compared with more than 50% in LMICs.3 In many parts 
of the world, patients do not have adequate access to 
effective treatment and treatment costs are often borne 
by the men and their families—a major cause of hardship.
Over the coming decade, the numbers of men in older 
age groups will increase, leading to a rising challenge to 
already stretched health-care systems.7 With variable 
public health-care systems globally and increased 
prevalence of advanced prostate cancer, this disease is 
set to become a much bigger burden for health-care 
providers and patients in the coming decades.
Prostate cancer has been the focus of much research 
in recent years with treatment advances ranging from 
robot-assisted surgery and high-precision radiotherapy 
for curative treatment to a growing number of new 
therapies for advanced disease. Genomic tools and 
imaging, particularly prostate-specific membrane 
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